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Abstract 
Background&Aims: Autoimmune chronic thyroiditis (ACT) is 
frequently associated with diabetes mellitus (DM) in clinical practice. The 
purpose of this study is to assess the prevalence of ACT in a group of adults 
with DM and other changes in glycemic balance. 
Methods: The studied group was of 650 people with DM and other changes 
in glycemic balance, aged between 18 - 79 years. The methods of 
investigation were represented by clinical, imaging, biochemical, hormonal 
and immunological parameters. 
Results: The prevalence of ACT in the study group was 32% (33.33% F and 
19.35% M, p = 0.024, X2 = 5.04). ACT prevalence was 83.33% for DM type 
1 (85.45% F and 60% M, p = 0.143, X2 = 2.14), 26.55%  for DM type 2 
(27.38% F and 21.05% M, p = 0.41, X2 = 0.68), 28.41% for impaired 
glucose tolerance (IGT)  (29.47% F and 10% M, p = 0.184, X2 = 1.76), and 
24.78% for impaired fasting glucose tolerance (IFG) (26.85% F and 0% M, p 
= 0.07, X2 = 3.21). Significant differences regarding ACT prevalence were 
found between the group with DM type 1 and type 2 and other changes in 
glycemic balance (83.33% vs. 26.55%, p <0.001, X2 = 69.33 for type 2 
diabetes, 83.33% vs. 28.41%, p <0.001, X2 = 55.95 for IGT, 83.33% vs. 
24.78%, p <0.001, X2 = 55.01 for IFG). 
Conclusion: ACT has prevailed in females and in the group with type 1 
diabetes due to autoimmune origin, part of the polygalndular autoimmune 
syndrome type III.  
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Introduction 
Thyroid disorders are frequently associated with diabetes in clinical 
practice. In type 1 diabetes, because autoimmune etiology it is often 
associated with autoimmune thyroid disease (chronic autoimmune 
thyroiditis, Basedow-Graves disease).  
Hashimoto's thyroiditis is a condition caused by inflammation of the 
thyroid gland. It is an autoimmune disease, which means that the body 
inappropriately attacks the thyroid gland--as if it was foreign tissue. The 
underlying cause of the autoimmune process still is unknown. Hashimoto's 
thyroiditis tends to occur in families, and is associated with a clustering of 
other autoimmune conditions such as type 1 diabetes, and celiac disease. 
Hashimoto's thyroiditis is 5-10 times more common in women than in men 
and most often starts in adulthood. Blood drawn from patients with 
Hashimoto's throiditis reveals an increased number of antibodies to the 
enzyme, thyroid peroxidase an enzyme (protein) found within the thyroid 
gland. As result of the antibodies' interaction with the enzyme, inflammation 
develops in the thyroid gland, the thyroid gland is destroyed, and the patient 
ultimately is rendered hypothyroid (too little thyroid hormone). 
The disease begins slowly. It may take months or even years for the 
condition to be detected. Chronic thyroiditis is most common in women and 
people with a family history of thyroid disease. It affects between 0.1% and 
5% of all adults in Western countries. 
Hashimoto's disease may, in rare cases, be associated with other 
endocrine disorders caused by the immune system. 
Hashimoto's thyroiditis is the most common cause of hypothyroidism 
in the United States.  
Hypothyroidism is very common and is estimated to affect 3%-5% of 
the adult population. It is more common in women than in men, and the risk 
of developing hypothyroidism increases with advancing age (Hypponen et al, 
2000). 
Because patients with organ-specific autoimmune disease are at risk 
of developing other autoimmune diseases, and thyroid disorders are more 
common in women, it is not surprising that 30% of women with type 1 
diabetes presents thyroid damage. Postpartum thyroiditis rate in diabetic 
patients is three times higher than in healthy women (Hypponen et al, 2000). 
Type 1 diabetes is commonly associated with endocrine and systemic 
disease with autoimmune etiology as Graves-Basedow disease, Hashimoto's 
thyroiditis, Addison's disease, celiac disease, pernicious anemia, myasthenia 
gravis, vitiligo, etc. (Armengol et al, 2003).  
From people with type 1 diabetes, ≈ 1-20 patients are generally 
affected by hypothyroidism (Diabetes Prevention Program Research Group, 
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2002). The frequency of DM type 1 association with hypothyroidism varies 
from 0.7% to 4% (American Diabetes Association, 2001). 
A particular association of DM type 1 with hypo-or hyperthyroidism, 
is characteristic to polyglandular autoimmune syndrome (PAS). There are 3 
polyglandular autoimmune syndromes.  
Polyglandular autoimmune syndrome type I (PAS I) is a recessive 
autosomal disorder caused by a mutation on the short arm of chromosome 
21, characterized by the triad of mucocutaneous candidiasis, 
hypoparathyroidism and Addison's disease (Aldasouqi et al, 2006, Myhre et 
al, 2001). 
Polyglandular autoimmune syndrome type II (PAS II) (Sivarajah  
et al, 2006, Betterle et al, 2004) is the most common 
immunoendocrinophathy. It occurs in adulthood, affecting mostly women. It 
is characterized by the appearance in the same person of two or more of the 
following diseases: Addison's disease, Graves-Basedow's disease, thyroiditis 
with autoimmune etiology, type I diabetes mellitus, primary hypogonadism, 
myasthenia gravis, celiac disease. 
Polyglandular autoimmune syndrome type III (PAS III) (Aung et 
al, 2006) is a PAS II syndrome without adrenocortical involvement. It 
comprises a group of autoimmune disorders generally characterized by 
glandular insufficiency. One fourth of the patients with the hypofunction of 
one gland present other endocrine glands hypofunction, too. This syndrome 
is associated with the following diseases: celiac disease, hypogonadism, 
myasthenia gravis, sarcoidosis, Sjogren's syndrome, rheumatoid arthritis, 
gastric cancer, malabsorption due by pancreatic exocrine deficiency time, 
and can be classified into 3 categories: 
  - PAS type III a - autoimmune thyroiditis with DM type 1  
 -  PAS type III b - autoimmune thyroiditis with pernicious anemia  
 - PAS type III c - autoimmune thyroiditis with vitiligo and/or 
alopecia and/or other autoimmune diseases 
 In the case of associations between IGT and IFG with thyroid 
diseases, these usually appear as thyroid hormones excess. These 
associations are more frequently at women.  
 In a US study it is show that in the patients with thyroid diseaseses, 
glucose intolerance was present in 38% cases, and incidence of clinical 
diabetes was ≈ 2-3 % (Wartofsky, 2000, Werner et al, 2000).  
Another authors show a prevalence of thyroid diseases at patients 
with DM type 2 at 2.5%, the most freuently thyroid disease being subclinical 
hypothyroidism  (4,1%) (Radaideh et al, 2004). 
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Material And Methods 
Investigated population  
650 people with diabetes and other changes in glycemic balance (588 
F and 62 M) aged between 18 and 79 years represented the study group.  
Depending on glycemic balance the group was divided into:  
- The group with DM type 1 - 60 
- The group with DM type 2 - 290 
- The group with IGT - 183 
- The group with IFG – 117 
Figure 1. Cases distribution according to the type of changes in glycemic balance 
 
Methods of investigation  
The methods of investigation were represented by clinical data - case 
history, current status, imagistic- thyroid ultrasound, biochemical - for 
glycemic balance: fasting blood glucose, glycosylated hemoglobin, 
investigation of the thyroid gland: TSH, FT4, FT3, thyroid antibodies. 
Determination of plasma glucose was performed by enzyme 
technique with glucosooxidasis. Normal values were taken between 70 - 110 
mg%; diabetes mellitus - values equal or over 126 mg%, impaired glucose 
tolerance - values between 110 - 125 mg% and the OGTT at 2 h between 140 
- 200 mg% and impaired fasting glucose - values between 110 - 125 mg% 
and OGTT at 2 h under 140 mg%.  
Determination of HbA1c was achieved through the DiaStat for 
measuring HbA1c reported to the total HbA.  
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To determine the TSH level in plasma, the free fraction of 
triiodotironin (FT3), and the plasma free fraction of thyroxin (FT4) were 
performed a quantitative method ARCHITECT; witch is an immunological 
method, Chemilumnescent Micro particle Immunoassay (CMIA). Normal 
values were following: TSH = 0.465-4.68 Miu/ml, FT3 = 3.69 -10.4 pmol/l, 
FT4 = 10-28.2 pmol/l. 
The immunological parameters were represented by autoimmune 
thyroid markers - antibodies (antiTPO and antiTg antibodies).  
To determine serum levels of antiTPO antibodies it was used the kit 
AxSYM antiTPO, an immunological method (Micro particle Enzyme 
Immunoassay) (MEIA). Normal values:  antiTPO antibodies <35 IU/ml.  
To determine serum levels of antiTg antibodies it was used the kit 
AxSYM antiTg, a MEIA method as well (Micro particle Enzyme 
Immunoassay). Normal values: antiTg antibodies <55 IU/ml.  
Thyroid ultrasound was performed in all cases and allowed us to 
measure thyroid volume, thyroid study and the changes in parenchyma’s 
density.  
An increased density, uniform, characterizes normal thyroid parenchyma 
easily distinguished from the neck muscles that are hypo dens.  
Inflammatory processes and autoimmune pathology appears hypo 
dens.  The scale was assessed as being discreet +, moderate ++ and marked 
+++.  
In the autoimmune thyroid disease the parenchyma of the gland 
appears hypo dens.  
Chronic autoimmune thyroid disorder appears with a hypoecogenity 
of the parenchyma and normal or increased thyroid volume.  
 
Statistical analysis 
For statistical analysis we used Microsoft Excel and POP Tools from 
Microsoft Office 2003 and EPI 2000 program. To measure the quantitative 
variables were determined average and standard deviation, and to assess the 
gender differences and other differences we used the unpaired t test and 
ANOVA test, considering statistically significant a p < 0.05. 
 
Results and discussion 
Adults group included 650 people, young adults, adults and the 
elderly, aged between 17 and 79 years (Table I). It consisted of subjects with 
diabetes which in time present thyroid diseases and subjects with thyroid 
disease who have developed glucose metabolism disorders or diabetes.  
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Table I. Distribution according to age and gender of adults group 
Age Cases number Female Male 
n % n % n % 
18 – 19 years 11 1.7 10 90.9 1 9.1 
20 – 29 years 29 4.46 27 93.1 2 6.9 
30 – 39 years 48 7.38 43 89.58 5 10.42 
40 – 49 years 168 25.84 141 83.93 27 16.07 
50 – 59 years 219 33.7 209 95.43 10 4.57 
60 – 69 years 118 18.15 112 94.91 6 5.09 
70 – 79 years 57 8.77 46 80.7 11 19.3 
 
Adults group was subdivided according to the type of change in 
glycemic balance in four subgroups (Fig. 1):  
- group with DM type 1 with 60 cases (9.23%)  
- group with DM type 2 with 290 cases (44.61%)  
- IGT group with 183 cases (28.15%)  
- IFG group with 117 cases (18%) 
DM type 1 represent 5 – 10 % from all cases with DM (1.4 million 
persons in US and 10 – 20 millions persons in all the world). (Şerban V, 
2010) 
 More than half DM type 1 cases are diagnosed after 15 years. In 
adult, most DM type 1 cases are mask by a false diagnostic of DM type 2, for 
a long or a short period of time. (Şerban V, 2010) 
 Information about DM type 1 incidence are little, but its incidence 
decrease in the 3rd decade of life and increase between 5 and 7 decade of 
life. (Şerban V, 2010) 
 About the gender, in areas with DM type 1 higher incidence, in adult, 
men have a higher risk, compare with women. (Şerban V, 2010)  
 DM type 2 represent 90 – 95% from all cases with DM.  
 In the country in course of development, prevalence peak is at 40 – 
45 age, while in develop country, this is above 60 years. (Şerban V, 2010) 
 In a study perform in Germay, in 2000, DM type 2 prevalence was 
16.7% at men and 8.6% in women, between 50 -59 years, and 23.2% at men 
and 17% at women between 70 and 74 years. (Rathmann et al, 2003) 
 AusDiab study show that DM type 2 affect 2.7% of men and 2.2% of 
women with age between 35 and 44 years, and 23.1% from men and 22.7% 
from women with age above 75 years. (Şerban V, 2010) 
 NHANES III study reveal the same prevalence increase tendency 
with age: 5.9 % at men and 4.8% at women between 40 – 49 years and 19.2 
% at men and 16.6% at women after 75 years. (Şerban V, 2010) 
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 Regarding the gender, the prevalence is higher in male, in the case of 
population with better economic situation, from Europe and US, and a 
preponderence of female in the rural areas. (Şerban V, 2010) 
In the study group, we had a predominance of females, because of the 
association of DM with thyroid disorder, diseases that prevail in women.  
The current average age and the onset average age of DM in the 
adult’s subgroups with different changes in glucose metabolism is shown in 
Table II.  
Table II. Distribution of adult’s subgroups with different changes in glucose metabolism by 
current age and by onset age 
Para 
meters 
Cases 
num 
ber 
Average Standard deviation Median Minimum Maximum 
DM type 1 
Onset age 
(years) 60 30.46 22.94 24.5 0 63 
Current age 
(years) 60 46.08 18.95 43 18 72 
DM type 2 
Onset age 
(years) 290 51.86 10.3 51 20 79 
Current  age 
(years) 290 55.43 10.73 54 20 79 
IGT 
Onset age 
(years) 183 48.84 10.61 50 17 76 
Current  age 
(years) 183 49.32 10.64 51 17 76 
IFG 
Onset age 
(years) 117 50.7 12.76 52 20 73 
Current age 
(years) 117 50.88 12.69 52 20 73 
 
The onset average age of type 1 diabetes corresponds with the 
literature, because it is known that type 1 diabetes usually occurs before 30 
years. Sometimes it may appear after 30 years, being labeled initially as type 
2 diabetes later prove to be a LADA type.  
NHANES study estimated that the prevalence of type 1 diabetes 
diagnosed between 30-74 years in the U.S. population is about 0.3% (0.1% 
from 0.6% between 30-49 years and 65-74 years) (Karvonen et al, 2003).  
The group of adults with type 2 diabetes included 290 people, young 
adults, adults and the elderly, ages 20 -79 years. 
The onset age of type 2 diabetes corresponds with the literature, 
because it is known that type 2 diabetes usually occurs after 40 years. 
DECODE study showed that in Europe type 2 diabetes met frequently 
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between 40-59 years, incidence was higher in women and in the white 
population (The DECODE Study Group, 2003). AusDiab study showed that 
the prevalence of type 2 diabetes increases with age, from 2.7% in men and 
2.2% in women between 35-44 years to 23.5% and 22.7% at 75 years and 
over (Dunstan et al, 2002). Also, in the Mexican population, the prevalence 
of type 2 diabetes increases from 4.2% and 3.2% for men and for women 
between 35-39 years at 23.1% for men and at 41.7% for women between 60-
64 years (Qiao et al, 2004). 
Adults group with IGT involving 183 people, young adults, adults 
and elderly, aged 17-76 years.  
Adults group with IFG included 117 people, young adults, adults and 
the elderly, ages 20 -73 years.  
The prevalence of IGT and IFG in Europe and Asia was assessed by 
2 studies: DECODE and DECODA. In Europe, the prevalence of IGT was 
less than 15% between 30-59 years and 30% over 60 years. IGT incidence 
increases linearly with age, while IFG not (Qiao et al, 2004). 
The prevalence of ACT in the study group was 32% (33.33% F and 
19.35% M, p = 0.024, X2 = 5.04).  
ACT prevalence in type 1 diabetic group was 83.33% (85.45% F and 
60% M, p = 0.143, X2 = 2.14), 26.55% in type 2 diabetic group (27.38% F 
and 21.05% M, p = 0.41, X2 = 0.68), 28.41%  in IGT group (29.47% F and 
10% M, p = 0.184, X2 = 1.76), and 24.78% in IFG group (26.85% F and 0% 
M, p = 0.07, X2 = 3.21).  
In the case of Hashimoto's thyroiditis, at adult, the incidence is 
estimated at 3.5 for women and 0.8 /1.000/year at men. The incidence is 
higher in geographic areas with adequate or increased intake of iodine and 
limited in ones with iodine deficiency.  
A number of studies show the association between thyroid disease 
with diabetes and other changes in glycemic balance. The most common 
thyroid disorders are autoimmune ones in type 1 diabetes and these 
accompanied by thyrotoxicosis for type 2 diabetes and other changes in 
glycemic balance. 
A study in the Czech Republic shows that the prevalence of thyroid 
disease in patients with diabetes is 2-3 times higher than in non-diabetic 
patients (Sivarajah et al, 2006). It increases with age and is strongly 
influenced by female gender and autoimmune diabetes (Sivarajah et al, 
2006(.  
Perros et al. (1995) showed in a study on 1310 adult patients with 
DM that the prevalence of thyroid disease was 13.4%, higher in women with 
type 1 diabetes (31.4%) and lower in men with type 2 diabetes (6.9%). 
Newly diagnosed thyroid disease was present in 6.8% of cases, on the first 
place being subclinical hypothyroidism (4.8%), followed by manifest 
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hypothyroidism (0.9%), subclinical hyperthyroidism (0.5%) and clinically 
hyperthyroidism (0.5%). Female patients with type 1 diabetes had the highest 
risk of developing thyroid disease (12.3%), but all the patients from the study 
group had a higher incidence of thyroid disease compared to the general 
population. This study suggests that thyroid function should be investigated 
in diabetic patients annually to detect asymptomatic thyroid damage with 
increased frequency in the diabetic population (Radaideh et al, 2006) 
Regarding gender distribution, we found a predominance of females 
in the study group, aspect consistent with the literature as thyroid disorders 
are more common in women.  
In the case of Hashimoto's thyroiditis, the ratio F/M was 15.6/1 in the 
case of the group with type 1 diabetes, 8.6/1 for DM type 2, 51/1 for IGT and 
29/0 for IFG. In literature it was found that the incidence is 10 to 15 times 
more common in women (Orlander et al, 2005). 
The distribution by onset age of thyroid disease is shown in Tab. III.  
Table III. The onset average age of ACT disease in the studied group 
Parameters Cases number Average Standard deviation Median 
DM type 1 50 42.78 18.17 42 
DM type 2 77 48.7 10.31 49 
IGT 52 41.48 8.64 42.5 
IFG 29 51.2 15.14 56 
 
Thus, in the case of Hashimoto's thyroiditis, onset age is between 30-
50 years in females and between 40-65 years in males [18]. 
Table IV. ACT duration at adult studied group 
Parameters Cases number Average 
Standard 
deviation Median Minimum Maximum 
DM type 1 50 4.3 3.98 2.5 0 12 
DM type 2 77 5.57 7.49 3 0 36 
IGT 52 5.07 8.11 1 0 38 
IFG 29 3.51 5.69 1 0 23 
 
Table V. The interval of appearence between ACT disease and differents changes in 
glycemic balance 
Time interval DM type 1 DM type 2 IGT IFG 
DM after ACT 
< 5 years 36% 63.63% 71.5% 75.6% 
5 – 10 years 2% 10.33% 9.6% 1.03% 
10 – 15 years - 7.73% 7.6% 6.85% 
15 – 20 years - 2.53% 5.7% 3.44% 
20 – 25 years - 1.23% 1.92% 3.44% 
25 – 30 years - - 1.92% - 
> 30 years - 2.53% 1.92% - 
ACT after DM 
< 5 years - 10.33% - - 
5 – 10 years 14% - - - 
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10 – 15 years 6% - - - 
15 – 20 years 8% - - - 
20 – 25 years 2% - - - 
25 – 30 years 24% 1.23% - - 
> 30 years 8% - - - 
 
Regarding the interval of appearence between ACT disease and 
differents changes in glycemic balance, in the case of DM type 1 we found 2 
situations: appearence of DM type 1 after ACT, mostly in the first 5 years 
and ACT after DM type at a variable period of time, due to the autoimmune 
origin of this 2 diaeases. In the case of DM type 2, IGT and IFG, there 
appear after ACT at a variable peroid of time, mostly in the first 5 years, 
probably because of treatment of ACT with thyroid hormones. Also, in the 
caee of DM type 2 we have appearence of ACT after DM type 2, but this 
association was random.  
Significant differences regarding ACT prevalence were found 
between the group with diabetes type 1 and type 2 diabetes and other 
changes in glycemic balance (83.33% vs. 26.55%, p <0.001, X2 = 69.33 for 
type 1 diabetes and type 2 diabetes, 83.33% vs. 28.41%, p <0.001, X2 = 
55.95 for type 1 diabetes and IGT, 83.33% vs. 24.78%, p <0.001, X2 = 55.01 
for type 1 diabetes and IFG), but not between type 2 diabetes and other 
changes in glycemic balance (26.55% vs. 28.41%, p = 0.65, X2 = 0.2 for type 
2 diabetes and IGT, 26.55% vs. 24.78%, p = 0.71, X2 = 0.13 for type 2 
diabetes and IFG, 28.41% vs. 24.78%, p = 0.48, X2 = 0.48 for IGT and IFG. 
 
Conclusion 
ACT has prevailed in females and in the group with type 1 diabetes 
due to autoimmune origin, part of the polyglandular autoimmune syndrome 
(PAS) type III A.  
In the case of DM type 2, IGT and IFG, these appear after ACT, at a 
variable peroid of time, mostly in the first 5 years, probably because of 
treatment of ACT with thyroid hormones. 
It is useful to determine antithyroid antibodies in patients with type 1 
diabetes to detect early ACT because it may progress with hypothyroidism 
(risk of atherosclerosis and associated cardiovascular diseases).  
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